GlobeNewswire·Apr 13, 2026, 4:01 PM ET

Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock

Allogene Therapeutics intends to sell $175 million of common stock in an underwritten public offering.
The company plans to grant underwriters a 30-day option to purchase up to an additional $26.25 million of shares.
Net proceeds will be used for general corporate purposes, including clinical trials, research & development, administrative expenses, & capital expenditures.
Goldman Sachs, Jefferies, & TD Cowen are serving as joint book-running managers, while TPG Capital BD acts as co-manager.
The offering is conducted under a shelf registration statement declared effective on April 25, 2024.
A preliminary prospectus supplement will be filed with the SEC & is available on the SEC website.
Allogene is a clinical-stage biotechnology company developing off-the-shelf AlloCAR T products for cancer & autoimmune diseases.
Actual completion, timing, or size of the offering is subject to market conditions & customary closing requirements.